Crossmark

Harnessing the Immune System in Pancreatic Cancer

Crossref DOI link: https://doi.org/10.1007/s11864-018-0566-5

Published Online: 2018-08-20

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Das, Satya

Berlin, Jordan

Cardin, Dana
License Information

Text and Data Mining valid from 2018-08-20
More Information

Article History

First Online: 20 August 2018

Compliance with Ethical Standards

:

: Satya Das has received compensation from Targeted Oncology for service as a consultant (Clinical Congress Consultants).Dana B. Cardin has received research funding from Celgene, EMD Serono, Hoffman-La Roche, Incyte, Oncolytics Biotech, Synta Pharmaceuticals, Bristol-Myers Squibb, Advaxis, and Lilly, and has received compensation from Cornerstone Pharmaceuticals, Rafael Pharmaceuticals, and AbbVie for service as a consultant.Jordan Berlin has received research funding from Novartis, AbbVie, Immunomedics, Taiho, Genentech/Roche, Bayer, Incyte, Pharmacyclics, Five Prime, EMD Serono, and Loxo.

: This article does not contain any studies with human or animal subjects performed by any of the authors.